The aim of this study is to find the right does of aspirin for chemoprevention in Lynch syndrome. The CAPP3 study is endorsed by InSiGHT.

The Cancer Prevention Project 3 (CAPP3) will focus on finding the right dose of aspirin for people with a mismatch repair gene defect, the underlying cause of Lynch syndrome. Three thousand people who have Lynch syndrome will be invited to take part in a dose non-inferiority trial.